<DOC>
	<DOC>NCT02744833</DOC>
	<brief_summary>This study will evaluate the safety profile of GMI-1271 and its effect on thrombus resolution in patients with distal calf vein Deep Venous Thrombosis (DVT).</brief_summary>
	<brief_title>Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>Age 1875 years Male or female Diagnosed with acute isolated calf vein Deep Venous Thrombosis (DVT) Willing and able to participate in all required evaluations and procedures in this study protocol History or presence of clinically significant medical condition or disease in the opinion of the principal investigator Uncontrolled acute lifethreatening bacterial, viral or fungal infection Unable to be treated with systemic anticoagulants Current use of immunosuppressants, antiplatelets (other than aspirin), anticoagulants, and/or antiepileptics Diagnosis of acute leukemia or multiple myeloma undergoing active treatment or maintenance treatment within the past 5 years Current or recent cancer treatment Major surgery within 21 days or planned surgery during the study period Female subjects who are pregnant or breastfeeding Known history of HIV, Hepatitis B or Hepatitis C Alcoholism or drug use Clinically significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>DVT</keyword>
</DOC>